Description : |
CD22 is a 135 kDa B-cell restricted sialoglycoprotein that binds to oligosaccharides containing 2-6-linked sialic acid residues.
It is present in the cytoplasm of nearly all B-lineage cells and is also expressed on the surface of B-cells during advance
stages of differentiation. Although the exact physiological function of CD22 is unclear, it appears to play a role in
B-cell activation and to act as an adhesion molecule. The potential therapeutic use of CD22 and anti-CD22 may be useful
in diagnostic and/or treatment of leukemia, lymphoma, non-Hodgkin's lymphoma and certain autoimmune conditions.
(Cesano A. and Gayko U. Semin. Oncol. Apr. 2003 (2): 253-257). Recombinant human CD22 is a soluble 75.0 kDa
(666 amino acid residues) protein which corresponds to the extracellular domain of CD22.
|
Catalog #: |
001-HCD22 |
Source : |
CHO cells (Chinese Hamster Ovarian cells) |
Formulation : |
The sterile filtered solution was lyophilized from 1 x PBS, pH 7.2 |
Stability : |
The lyophilized protein is stable for a few weeks at room temperature, but best stored at -200C.
Reconstituted CD22 should be stored in working aliquots at -200C. |
Purity : |
Greater than 98% by SDS-PAGE and HPLC analyses.
Endotoxin level is less than 0.1 ng per μg (1EU/μg).
|
Reconstitution : |
We recommend a quick spin followed by reconstitution in water to a concentration of 0.1-1.0 mg/ml.
This solution can then be diluted into other aqueous buffers and stored at 40C
for 1 week or stored at -200C for future use. |
Biological Activity : |
Determined by it's ability to induce cytotoxicity
in Raji cells. The ED50 for this effect is 10 - 15 ug/ml.
|
PubMed Link : |
Human CD22 |
Usage: |
For research only. Not for use in diagnostic or therapeutic procedures. |
Country of Origin : |
USA |
